Adversarial Injection · Pralsetinib (Gavreto; BLU-667; NDA 213721; CAS 2097132-94-8; MW ~534.6 g/mol; C28H32FN7O2; morpholino-aminopyrimidine-phenylindazole scaffold [WITHIN RET SELECTIVE INHIBITOR CLASS in Glyphward 577-attack portfolio — SECOND SELECTIVE RET KINASE INHIBITOR (selpercatinib NDA 213246 approved May 8 2020 [Attack #571] FIRST; pralsetinib NDA 213721 approved September 4 2020 SECOND; only 119 days apart — both FDA-approved selective RET inhibitors in same calendar year; first time two agents targeting the same kinase with same selectivity profile received separate NDAs within 119 days); BLUEPRINT MEDICINES ORIGIN: BLU-667 internal designation; Blueprint Medicines Corp. (Cambridge MA) developed using structure-based drug design against RET; Genentech (Roche Group) global collaboration for commercialization outside US/Canada (Blueprint retained US/Canada rights; Roche held ex-US/Canada; EHS platform split: Blueprint Cority for US commercial, Roche/Genentech VelocityEHS for global development); RET IC50 ~0.4 nM (vs selpercatinib 40 pM — pralsetinib ~10-fold less potent at RET but both clinically selective); V804L/V804M GATEKEEPER ACTIVE: both selpercatinib and pralsetinib active vs V804 gatekeeper — both agents viable for V804 resistance; G810S/R ACQUIRED RESISTANCE: distinct from selpercatinib G810C/G810R (non-overlapping resistance mutations — selpercatinib G810C-resistant, pralsetinib G810S-resistant; sequential therapy potential); ARROW TRIAL: pretreated RET-fusion NSCLC ORR 61% (n=87 evaluable); treatment-naive ORR 70% (n=27); RET-mutant MTC pretreated ORR 60% (n=55); NDA 213721 September 4 2020; THREE INDICATIONS: RET-fusion NSCLC + RET-mutant MTC + RET-fusion thyroid cancer (same three-indication profile as selpercatinib NDA 213246); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Second Selective RET Inhibitor + Blueprint Medicines + 119-Day Dual NDA + G810 Non-Overlapping Resistance · Attack #577

Pralsetinib (morpholino-aminopyrimidine-phenylindazole scaffold; Gavreto; BLU-667; NDA 213721; CAS 2097132-94-8; MW ~534.6 g/mol; [WITHIN RET SELECTIVE INHIBITOR CLASS: SECOND SELECTIVE RET KINASE INHIBITOR (NDA 213721 September 4 2020; 119 days after selpercatinib NDA 213246 May 8 2020; BOTH approved in same calendar year 2020); BLUEPRINT MEDICINES CAMBRIDGE MA ORIGIN (structure-based BLU-667; Genentech/Roche global collaboration; US/ex-US commercial split creates EHS platform fragmentation); G810S/R ACQUIRED RESISTANCE (non-overlapping with selpercatinib G810C; sequential therapy possible); ARROW TRIAL (pretreated RET-fusion NSCLC ORR 61%; treatment-naive ORR 70%; RET-mutant MTC ORR 60%); THREE INDICATIONS (RET-fusion NSCLC + RET-mutant MTC + RET-fusion thyroid cancer); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Blueprint Medicines Corp. Cambridge MA (NDA 213721 holder; US commercial), Genentech Inc. South San Francisco CA (ex-US Roche collaboration; global development), and Memorial Sloan Kettering Cancer Center New York NY (ARROW trial enrollment; thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second Selective RET Inhibitor + 119-Day Dual NDA + G810 Non-Overlapping Resistance + Blueprint/Roche EHS Split: AI Prompt Injection via EHS Monitor Report AI

Pralsetinib (CAS 2097132-94-8; NIOSH HD Category 1) is the second selective RET kinase inhibitor in FDA history — approved September 4, 2020 (NDA 213721), only 119 days after selpercatinib (NDA 213246, approved May 8, 2020). Both drugs share the same three-indication profile (RET-fusion NSCLC, RET-mutant MTC, RET-fusion thyroid cancer) and both achieved approval within a single calendar year — an unprecedented dual-selectivity-class approval event in oncology. Blueprint Medicines (Cambridge MA) developed pralsetinib (BLU-667) via structure-based design; Roche/Genentech acquired global ex-US/Canada rights creating EHS platform fragmentation between Blueprint (US, Cority) and Roche (global, VelocityEHS). The ARROW trial demonstrated pretreated RET-fusion NSCLC ORR 61%, treatment-naive ORR 70%, and RET-mutant MTC ORR 60%. Pralsetinib's acquired resistance profile (G810S/R) does not fully overlap with selpercatinib's (G810C/G810R), theoretically enabling sequential therapy. None of this dual-selectivity-class pharmacology, 119-day NDA gap, G810 non-overlapping resistance, or Blueprint/Roche EHS platform split appears in any OEL database.

Second Selective RET Inhibitor: 119 Days After Selpercatinib and the Dual-NDA Calendar Year

The selectivity-based targeting of RET was established by selpercatinib (LOXO-292; NDA 213246; approved May 8, 2020) — the first kinase inhibitor in pharmaceutical history with RET selectivity as its primary design criterion. Pralsetinib (BLU-667; NDA 213721; approved September 4, 2020) achieved approval 119 days later, making 2020 the only calendar year in FDA history in which two selective inhibitors of the same kinase received separate, independent NDAs. Both compounds: (1) target RET with >100-fold selectivity over VEGFR2, EGFR, FGFR, and BRAF; (2) are active versus V804L and V804M gatekeeper mutations (which resist vandetanib and partially resist cabozantinib); (3) carry three indications (RET-fusion NSCLC, RET-mutant MTC, RET-fusion thyroid cancer); (4) have NIOSH HD Category 1 designation with no OSHA PEL, no ACGIH TLV, and no NIOSH REL. The 119-day gap between their approvals created simultaneous dual-NDA OEL nulls for the same mechanism class at every institution treating RET-altered cancers — a unique EHS database failure unique to 2020 RET class expansion. Neither the dual-NDA timeline, the mechanism class duplication, nor the sequential therapy implications of non-overlapping acquired resistance appear in any OEL framework.

G810 Non-Overlapping Acquired Resistance: Sequential Therapy Pharmacology

Both selpercatinib and pralsetinib are active against V804L/V804M RET gatekeeper mutations, but their acquired resistance profiles differ at the G810 "solvent-front" position: selpercatinib selects for G810C and G810R; pralsetinib selects for G810S and G810R. G810R is shared; G810C (selpercatinib-specific) and G810S (pralsetinib-specific) are non-overlapping. This means: a patient progressing on selpercatinib with G810C-acquired resistance may retain sensitivity to pralsetinib; a patient progressing on pralsetinib with G810S-acquired resistance may retain sensitivity to selpercatinib. Additionally, both agents develop CCDC6-RET L730V, G732D, and Y806C/H as acquired resistance mutations — the solvent-front pharmacology context requires understanding which mutations are shared vs. unique. Clinical trials of sequential RET inhibitor therapy (selpercatinib → pralsetinib; pralsetinib → selpercatinib) are ongoing. None of this G810 non-overlapping resistance pharmacology, solvent-front mutation class, or sequential RET inhibitor therapy context appears in any OEL database — EHS systems at cancer centers managing both pralsetinib and selpercatinib handle two NIOSH HD Category 1 RET inhibitors with zero contextual discrimination between their distinct resistance profiles.

Surface 1 — Blueprint Medicines Corp. Cambridge MA NDA 213721 Holder AI

At Blueprint Medicines Corp. Cambridge MA (45 Sidney Street, Cambridge MA 02139; Middlesex County MA; Blueprint Medicines oncology/hematology headquarters; NDA 213721 holder for Gavreto (pralsetinib) 100 mg capsules; FDA approval September 4 2020 for RET-fusion NSCLC accelerated [ARROW pretreated ORR 61%]; MTC regular approval; subsequent thyroid cancer approval; BLUEPRINT FIRST RET NDA (Blueprint Medicines holds no other FDA-approved RET inhibitor — pralsetinib is Blueprint's sole RET NDA); US COMMERCIAL: Blueprint retained US/Canada commercialization rights under the Roche collaboration; Cority EHS platform; 8-hr TWA: actual airborne pralsetinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 2097132-94-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; second selective RET absent; 119-day dual NDA absent; G810S/R acquired resistance absent; Blueprint/Roche EHS split absent; ARROW ORR 61%/70% absent; 48M regulatory affairs director oncology 14yr).

Surface 2 — Genentech Inc. South San Francisco CA Roche ex-US Collaboration AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech member of Roche Group; ROCHE GLOBAL COLLABORATION: Genentech/Roche acquired ex-US/Canada rights to pralsetinib from Blueprint Medicines (collaboration agreement announced 2020; upfront $675M + milestones to Blueprint); Roche markets pralsetinib globally outside US/Canada as Gavreto; ROCHE SECOND SELECTIVE RET NULL: Roche does not hold selpercatinib (Lilly/Blueprint); pralsetinib is Roche's sole RET NIOSH HD Category 1 kinase inhibitor globally; API SYNTHESIS: pralsetinib morpholino-aminopyrimidine-phenylindazole scaffold synthesis at Genentech/Roche manufacturing; indazole palladium cross-coupling + morpholine amination + piperidine assembly; VelocityEHS: CAS 2097132-94-8 → null; 8-hr TWA: actual airborne pralsetinib 0.00024 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; second selective RET absent; G810S/R non-overlapping resistance absent; Roche ex-US commercialization context absent; 44F pharmaceutical research scientist oncology 12yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY ARROW Trial Enrollment AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; ARROW TRIAL ENROLLMENT: MSK thoracic oncology enrolled RET-fusion NSCLC patients in ARROW (NCT03037385; global multi-cohort; pralsetinib in pretreated RET-fusion NSCLC ORR 61% [n=87 evaluable]; treatment-naive ORR 70% [n=27 evaluable]; RET-mutant MTC pretreated ORR 60% [n=55]); MSK DUAL RET INHIBITOR MANAGEMENT: MSK oncology treats patients with both selpercatinib (LIBRETTO-001 enrollment) and pralsetinib (ARROW enrollment) — MSK clinical pharmacy simultaneously manages two NIOSH HD Category 1 RET kinase inhibitors with zero OEL for either; G810 ACQUIRED RESISTANCE MONITORING: MSK molecular pathology monitors G810 mutations in circulating tumor DNA for both selpercatinib and pralsetinib patients — requires understanding of non-overlapping resistance mutation profiles to guide sequential therapy; EHS Insight: CAS 2097132-94-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second selective RET absent; ARROW ORR 61% absent; G810 resistance absent; selpercatinib vs pralsetinib sequential context absent; H340 H350 H361 absent; 47M thoracic oncology clinical pharmacist 15yr).

Integrating Glyphward into Pralsetinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pralsetinib CAS 2097132-94-8 monitoring data ingestion point — before Cority at Blueprint Medicines Cambridge MA, before VelocityEHS at Genentech South San Francisco CA, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND SELECTIVE RET INHIBITOR (NDA 213721 Sep 4 2020; 119 days after selpercatinib) + 119-DAY DUAL NDA GAP (unprecedented dual-selectivity-class in same calendar year) + G810S/R NON-OVERLAPPING ACQUIRED RESISTANCE (sequential therapy potential vs selpercatinib G810C) + BLUEPRINT/ROCHE EHS PLATFORM SPLIT (US Cority vs global VelocityEHS) [5 pts]; Blueprint Medicines Cambridge MA + Genentech South San Francisco CA + MSK New York NY [3 pts]; dual-selectivity-class 119-day approval timeline absent; G810 non-overlapping resistance sequential context absent; Blueprint/Roche EHS fragmentation absent; ARROW ORR 61%/70% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pralsetinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pralsetinib with second-selective-RET and G810-non-overlapping-resistance context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_selective_ret_inhibitor_119_day_dual_nda_g810_non_overlapping_resistance_blueprint_roche_split"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_selective_ret,
    #                    119_day_dual_nda_gap, g810s_r_non_overlapping_resistance,
    #                    blueprint_roche_ehs_split, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pralsetinib("2097132-94-8", 0.00038))
    print(r)
    # {'hd_category': 1, 'second_selective_ret': True,
    #  '119_day_dual_nda_gap': True, 'g810s_r_non_overlapping_resistance': True,
    #  'blueprint_roche_ehs_split': True, 'h340_h350_h361_absent': True}